Literature DB >> 28966130

Effect of cardamonin on hepatic ischemia reperfusion induced in rats: Role of nitric oxide.

Yara Atef1, Hassan M El-Fayoumi2, Yousra Abdel-Mottaleb1, Mona F Mahmoud3.   

Abstract

Ischemia reperfusion (I/R) injury is a cellular damage in a hypoxic organ following the restoration of oxygen delivery. It may occur during organ transplantation, trauma and hepatectomies. Nitric oxide (NO) effects during hepatic I/R are complicated. The iNOS-derived NO has a deleterious effect, whereas eNOS-derived NO has a protective effect in liver I/R. Cardamonin (CDN) is an anti-inflammatory molecule and a novel iNOS inhibitor, and Nω-Nitro-L-arginine (L-NNA) is a NOS inhibitor. L-Arginine is a precursor of NOS. This study was designed to investigate the possible protective effects of CDN on hepatic I/R and the role of NO. Wistar rats were randomly divided into 5 groups (Sham, I/R, CDN, L-NNA and L-arginine). Liver ischemia was induced for 45min then reperfusion was allowed for 1h. L-Arginine and CDN ameliorated the deleterious effects of I/R through reducing the oxidative stress and hepatocyte degeneration. Both molecules decreased the elevated inflammatory cytokines and increased the antiapoptotic marker, Bcl2. Both agents increased NO and eNOS expression and decreased iNOS expression. In conclusion, increased NO/eNOS and suppression of iNOS expression have protective effects on I/R injury. While inhibition of eNOS and reduction of NO have deleterious effects on I/R injury. For the first time, we demonstrated that cardamonin improved functional and structural abnormalities of the liver following I/R by improving oxidative stress and inflammation and increasing the availability of NO produced by eNOS. Treatment with cardamonin could be a promising strategy in patients with hepatic I/R injury in different clinical situations.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardamonin; Ischemia reperfusion; L-Arginine; L-NNA; NOS

Mesh:

Substances:

Year:  2017        PMID: 28966130     DOI: 10.1016/j.ejphar.2017.09.037

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Ameliorative effects of hydrogen sulfide (NaHS) on chronic kidney disease-induced brain dysfunction in rats: implication on role of nitric oxide (NO) signaling.

Authors:  Hassan Askari; Mohammad Foad Abazari; Pegah Ghoraeian; Sepehr Torabinejad; Maryam Nouri Aleagha; Reza Mirfallah Nassiri; Farshid Tahmasebi; Nairi Abedi; Sulail Fatima Rajani; Ali Salarian; Maryam Belaran; Mohammed Elshiekh; Nima Sanadgol
Journal:  Metab Brain Dis       Date:  2018-08-08       Impact factor: 3.584

Review 2.  New progress in understanding roles of nitric oxide during hepatic ischemia-reperfusion injury.

Authors:  Yi-Ping Zhang; Xin-Ran Liu; Mei-Wen Yang; Shu-Long Yang; Fen-Fang Hong
Journal:  World J Hepatol       Date:  2022-03-27

3.  Vildagliptin Attenuates Hepatic Ischemia/Reperfusion Injury via the TLR4/NF-κB Signaling Pathway.

Authors:  Iman O Sherif; Nora H Al-Shaalan
Journal:  Oxid Med Cell Longev       Date:  2018-10-14       Impact factor: 6.543

4.  Cardamonin Reduces Acetaminophen-Induced Acute Liver Injury in Mice via Activating Autophagy and NFE2L2 Signaling.

Authors:  Qiushi Xu; Yunhui Fan; Juan J Loor; Yusheng Liang; Xudong Sun; Hongdou Jia; Chenxu Zhao; Chuang Xu
Journal:  Front Pharmacol       Date:  2020-11-13       Impact factor: 5.810

Review 5.  Emerging roles of cardamonin, a multitargeted nutraceutical in the prevention and treatment of chronic diseases.

Authors:  Uzini Devi Daimary; Dey Parama; Varsha Rana; Kishore Banik; Aviral Kumar; Choudhary Harsha; Ajaikumar B Kunnumakkara
Journal:  Curr Res Pharmacol Drug Discov       Date:  2020-12-10

Review 6.  Effects of iNOS in Hepatic Warm Ischaemia and Reperfusion Models in Mice and Rats: A Systematic Review and Meta-Analysis.

Authors:  Richi Nakatake; Mareike Schulz; Christina Kalvelage; Carina Benstoem; René H Tolba
Journal:  Int J Mol Sci       Date:  2022-10-07       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.